| scholarly article | Q13442814 |
| P50 | author | Udai Banerji | Q41195747 |
| Johann de Bono | Q43249916 | ||
| Jaap Verweij | Q98683725 | ||
| P2093 | author name string | Adam Stewart | |
| Rebecca Kristeleit | |||
| Dionysis Papadatos-Pastos | |||
| Ferry Alm Eskens | |||
| Florence Raynaud | |||
| Leni van Doorn | |||
| Leon Hooftman | |||
| Martin Toal | |||
| Matthew Tall | |||
| Michelle Dawn Garrett | |||
| Phillip Debnam | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacodynamics | Q725307 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 2687-2694 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors | |
| P478 | volume | 18 |
| Q41553016 | Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets |
| Q35103514 | Antitumor activity in RAS-driven tumors by blocking AKT and MEK. |
| Q36446188 | Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells. |
| Q38210475 | Current and potential epigenetic targets in multiple myeloma. |
| Q38341369 | ELISA in the multiplex era: potentials and pitfalls. |
| Q43717425 | Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. |
| Q28076548 | Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? |
| Q26773803 | Epigenetic treatment of solid tumours: a review of clinical trials |
| Q60304301 | Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib |
| Q38947405 | HDACs and HDAC Inhibitors in Cancer Development and Therapy |
| Q95853354 | Histone Deacetylase Inhibitors: A Prospect in Drug Discovery |
| Q26778780 | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
| Q89685622 | Integrated assessment of viral transcription, antigen presentation, and CD8+ T cell function reveal multiple limitations of class I selective HDACi during HIV-1 latency reversal |
| Q35376207 | N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. |
| Q27022413 | New and emerging HDAC inhibitors for cancer treatment |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q37226511 | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| Q39405196 | Role of epigenetic modulation for the treatment of sarcoma. |
| Q38176396 | Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). |
| Q89169966 | Targeting Epigenetics in Cancer |
| Q55485574 | Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. |
| Q38231327 | Targeting the histone orthography of cancer: drugs for writers, erasers and readers |
| Q39113061 | The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway |
| Q90641451 | The great escape: tumour cell plasticity in resistance to targeted therapy |
| Q48136812 | Therapeutic effects of histone deacetylase inhibitors on kidney disease. |
| Q27000542 | Trials with ‘epigenetic’ drugs: An update |
| Q92408464 | Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics |
Search more.